CytomX Therapeutics, Inc. (CTMX)
CTMXNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$2.03
-0.1600 (-7.31%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $431.65m
- P/E
- –
- EPS, last 4 quarters
- $-0.5000
- Dividend yield
- –
- Day range
- –
- 52-week range
- $2.11 to $8.21
- Average volume
- 3.98m
- Previous close
- $2.19
Analysts
6 coveringBuy6 buy, 0 hold, 0 sell
Targets a year out average $12.83, +532.0% from here
Earnings
next estimate $-0.1000Next report
Dec 2025
-175.0%
Mar 2026
+28.6%
Jun 2026
+18.2%
Sep 2026
0.0%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $663.0k | $10.26m | $1.42m | $1.69m |
| Gross profit | $663.0k | $10.26m | $1.42m | $1.69m |
| Operating income | -$27.93m | -$19.67m | -$23.78m | -$23.50m |
| Net income | -$26.51m | -$18.25m | -$20.67m | -$20.00m |
Last four quarters: revenue $14.03m, margin -608.9%, free cash flow –
News
8 latest- CytomX Therapeutics Announces Q3 2026 Financial Results and Provides Business UpdateFintel · 4 days ago
- CytomX (CTMX) Q3 2026 Earnings Call TranscriptThe Motley Fool · 4 days ago
- CytomX Therapeutics Q3 Earnings Call HighlightsMarketBeat · 4 days ago
- CytomX Therapeutics (CTMX) Reports Q3 Loss, Lags Revenue EstimatesZacks · 4 days ago
- Qiagen (QGEN) Surpasses Q3 Earnings and Revenue EstimatesZacks · 5 days ago
- CytomX Secures FDA Fast Track For Varseta-M In Metastatic Colorectal Cancer RTTNews · Aug 27, 2026
- CytomX Therapeutics Q2 Earnings Call HighlightsMarketBeat · Aug 6, 2026
- CytomX Therapeutics (CTMX) Upgraded to Buy: Here's WhyZacks · Jul 8, 2026
The company
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked PROBODY therapeutics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY therapeutic platform, CytomX's vision is to create safer, more effective therapies for the treatment of cancer. CytomX's robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates, cytokines and T-cell engagers. CytomX's clinical-stage pipeline includes varsetatug masetecan (Varseta-M; CX-2051) and CX-801. Varseta-M is a masked, conditionally activated antibody drug conjugate armed with a topoisomerase-1 inhibitor payload and directed toward epithelial cell adhesion molecule (EpCAM). EpCAM is a highly expressed tumor antigen that has previously been undruggable due to expression on normal tissues.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- cytomx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.